Comparisons of immunosuppressive therapies. Treatment is defined as ever vs never exposure to the medications. Data are percentages of subjects taking each medication.
| Medication | CTD-ILD n = 76 | IPF, n = 148 | p | SSc-ILD, n = 26 | Non-SSC CTD-ILD, n = 50 | p |
|---|---|---|---|---|---|---|
| Cyclophosphamide | 10.5 | 8.1 | 0.5479 | 7.7 | 12.0 | 0.7078 |
| Azathioprine | 30.3 | 37.8 | 0.2613 | 11.5 | 40.0 | 0.0104 |
| Methotrexate | 18.4 | 1.4 | < 0.0001 | 7.7 | 24.0 | 0.1200 |
| Mycophenolate mofetil | 23.7 | 14.9 | 0.1027 | 11.5 | 30.0 | 0.0725 |
| Hydroxychloroquine | 22.4 | 6.1 | 0.0003 | 15.4 | 26.0 | 0.2921 |
| Prednisone | 57.9 | 48.7 | 0.1898 | 23.1 | 76.0 | < 0.0001 |
| TNF inhibitor | 21.1 | 0 | < 0.0001 | 0 | 32.0 | 0.0012 |
CTD-ILD: connective tissue disease-associated interstitial lung disease; IPF: idiopathic pulmonary fibrosis; SSc-ILD: systemic sclerosis-associated ILD; non-SSc CTD-ILD: nonsystemic sclerosis CTD-ILD; TNF: tumor necrosis factor.